Newron Pharmaceuticals SpA Market Cap ($235.69 Million)
Market Cap & Net Worth: Newron Pharmaceuticals SpA (NWRN)
Newron Pharmaceuticals SpA market cap. Newron Pharmaceuticals SpA (SW:NWRN) has a market capitalization of $235.69 Million (CHF186.42 Million) as of November 5, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #15689 globally and #170 in its home market, demonstrating a -1.54% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Newron Pharmaceuticals SpA's stock price CHF8.96 by its total outstanding shares 20805797 (20.81 Million). Also see cash flow conversion of Newron Pharmaceuticals SpA for how efficiently the company converts equity into cash flow.
Newron Pharmaceuticals SpA Market Cap History (2015–2026)
Newron Pharmaceuticals SpA market cap history from 2015 to 2026. Data shows change from $673.39 Million to $235.69 Million (-10.22% CAGR). Check Newron Pharmaceuticals SpA stock quote for real-time trading data and today's change.
Newron Pharmaceuticals SpA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Newron Pharmaceuticals SpA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Newron Pharmaceuticals SpA net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
32.80x
Newron Pharmaceuticals SpA's market cap is 32.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $530.03 Million | $6.73 Million | -$15.24 Million | 78.80x | N/A |
| 2017 | $305.13 Million | $13.43 Million | -$5.28 Million | 22.72x | N/A |
| 2018 | $147.57 Million | $4.03 Million | -$15.04 Million | 36.66x | N/A |
| 2019 | $167.03 Million | $7.04 Million | -$20.21 Million | 23.73x | N/A |
| 2020 | $56.55 Million | $5.26 Million | -$21.00 Million | 10.76x | N/A |
| 2021 | $42.61 Million | $5.76 Million | -$14.90 Million | 7.40x | N/A |
| 2022 | $40.77 Million | $6.09 Million | -$17.49 Million | 6.69x | N/A |
| 2023 | $130.21 Million | $9.06 Million | -$16.22 Million | 14.38x | N/A |
| 2024 | $235.42 Million | $51.39 Million | $15.84 Million | 4.58x | 14.86x |
| 2025 | $627.35 Million | $19.13 Million | -$13.24 Million | 32.80x | N/A |
Competitor Companies of NWRN by Market Capitalization
Companies near Newron Pharmaceuticals SpA in the global market cap rankings as of November 5, 2026. Also see NWRN total assets for a full breakdown of the balance sheet.
Key companies related to Newron Pharmaceuticals SpA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Newron Pharmaceuticals SpA (2015–2026)
Market capitalization of Newron Pharmaceuticals SpA from 2015 to today. Between 2015 and today, Newron Pharmaceuticals SpA's market cap moved from $673.39 Million to $ 235.69 Million, with a yearly change of -10.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF235.69 Million | -62.43% |
| 2025 | CHF627.35 Million | +166.48% |
| 2024 | CHF235.42 Million | +80.81% |
| 2023 | CHF130.21 Million | +219.35% |
| 2022 | CHF40.77 Million | -4.32% |
| 2021 | CHF42.61 Million | -24.65% |
| 2020 | CHF56.55 Million | -66.14% |
| 2019 | CHF167.03 Million | +13.19% |
| 2018 | CHF147.57 Million | -51.64% |
| 2017 | CHF305.13 Million | -42.43% |
| 2016 | CHF530.03 Million | -21.29% |
| 2015 | CHF673.39 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Newron Pharmaceuticals SpA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $235.69 Million USD |
| MoneyControl | $235.69 Million USD |
| MarketWatch | $235.69 Million USD |
| marketcap.company | $235.69 Million USD |
| Reuters | $235.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more